276 related articles for article (PubMed ID: 12467639)
1. Squalene epoxidase as hypocholesterolemic drug target revisited.
Chugh A; Ray A; Gupta JB
Prog Lipid Res; 2003 Jan; 42(1):37-50. PubMed ID: 12467639
[TBL] [Abstract][Full Text] [Related]
2. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
[TBL] [Abstract][Full Text] [Related]
3. Squalene monooxygenase - a target for hypercholesterolemic therapy.
Belter A; Skupinska M; Giel-Pietraszuk M; Grabarkiewicz T; Rychlewski L; Barciszewski J
Biol Chem; 2011 Dec; 392(12):1053-75. PubMed ID: 22050222
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S; Frishman WH
Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
[TBL] [Abstract][Full Text] [Related]
5. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
6. Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells.
Sawada M; Matsuo M; Hagihara H; Tenda N; Nagayoshi A; Okumura H; Washizuka K; Seki J; Goto T
Eur J Pharmacol; 2001 Nov; 431(1):11-6. PubMed ID: 11716837
[TBL] [Abstract][Full Text] [Related]
7. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Charlton-Menys V; Durrington PN
Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
[TBL] [Abstract][Full Text] [Related]
8. Potential role of nonstatin cholesterol lowering agents.
Trapani L; Segatto M; Ascenzi P; Pallottini V
IUBMB Life; 2011 Nov; 63(11):964-71. PubMed ID: 21990243
[TBL] [Abstract][Full Text] [Related]
9. (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
Gotteland JP; Brunel I; Gendre F; Désiré J; Delhon A; Junquéro D; Oms P; Halazy S
J Med Chem; 1995 Aug; 38(17):3207-16. PubMed ID: 7650673
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts.
Matzno S; Yamauchi T; Gohda M; Ishida N; Katsuura K; Hanasaki Y; Tokunaga T; Itoh H; Nakamura N
J Lipid Res; 1997 Aug; 38(8):1639-48. PubMed ID: 9300786
[TBL] [Abstract][Full Text] [Related]
11. Effect of an inhibitor of squalene epoxidase, NB-598, on lipid metabolism in Hep G2 cells.
Nagata Y; Horie M; Hidaka Y; Yonemoto M; Hayashi M; Watanabe H; Ishida F; Kamei T
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):436-40. PubMed ID: 1606641
[TBL] [Abstract][Full Text] [Related]
12. Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography-mass spectrometry targeted metabonomic profiling.
Bahety P; Van Nguyen TH; Hong Y; Zhang L; Chan ECY; Ee PLR
Eur J Nutr; 2017 Feb; 56(1):29-43. PubMed ID: 26428672
[TBL] [Abstract][Full Text] [Related]
13. Regulation of squalene epoxidase in HepG2 cells.
Hidaka Y; Satoh T; Kamei T
J Lipid Res; 1990 Nov; 31(11):2087-94. PubMed ID: 1964954
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase.
Cattel L; Ceruti M; Balliano G; Viola F; Grosa G; Schuber F
Steroids; 1989; 53(3-5):363-91. PubMed ID: 2678608
[TBL] [Abstract][Full Text] [Related]
17. Green tea polyphenols: novel and potent inhibitors of squalene epoxidase.
Abe I; Seki T; Umehara K; Miyase T; Noguchi H; Sakakibara J; Ono T
Biochem Biophys Res Commun; 2000 Feb; 268(3):767-71. PubMed ID: 10679280
[TBL] [Abstract][Full Text] [Related]
18. NB-598: a potent competitive inhibitor of squalene epoxidase.
Horie M; Tsuchiya Y; Hayashi M; Iida Y; Iwasawa Y; Nagata Y; Sawasaki Y; Fukuzumi H; Kitani K; Kamei T
J Biol Chem; 1990 Oct; 265(30):18075-8. PubMed ID: 2211682
[TBL] [Abstract][Full Text] [Related]
19. Inactivation and activation of various membranal enzymes of the cholesterol biosynthetic pathway by digitonin.
Eilenberg H; Klinger E; Przedecki F; Shechter I
J Lipid Res; 1989 Aug; 30(8):1127-35. PubMed ID: 2504860
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.
Horie M; Hayashi M; Satoh T; Hotta H; Nagata Y; Ishida F; Kamei T
Biochim Biophys Acta; 1993 May; 1168(1):45-51. PubMed ID: 8504141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
